Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REPLIGEN CORP Director's Dealing 2022

Aug 17, 2022

30826_dirs_2022-08-17_ef2f4128-be93-45ae-9a47-f3ecbfc28679.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2022-08-16

Reporting Person: Snodgres Jon (Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-08-16 Common Stock M 3047 $86.10 Acquired 40234 Direct
2022-08-16 Common Stock M 970 $215.58 Acquired 41204 Direct
2022-08-16 Common Stock S 4298 $252.70 Disposed 36906 Direct
2022-08-16 Common Stock S 2400 $253.16 Disposed 34506 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-08-16 Stock Option (Right to Buy) $86.10 M 3047 Acquired 2030-02-27 Common Stock (3047) Direct
2022-08-16 Stock Option (Right to Buy) $215.58 M 970 Acquired 2031-02-24 Common Stock (970) Direct

Footnotes

F1: $252.70 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $252.16 to $253.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2: 1,524 shares vest and become exercisable on 2/27/2023.

F3: Shares vest and become exercisable as follows: 970 shares on 2/24/2023 and 970 shares on 2/24/2024.